NCT03012815View on ClinicalTrials.gov

Gabapentin for Alcohol Withdrawal Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
Alcohol Withdrawal Syndrome
Interventions
DRUG

Gabapentin

Gabapentin administered as a taper

DRUG

Benzodiazepines

Benzodiazepines administered using a symptoms triggered protocol

DRUG

Divalproex Sodium

Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER